Major differences in the characteristics of users of the copper intrauterine device or levonorgestrel intrauterine system at a clinic in Campinas, Brazil.


Journal

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174

Informations de publication

Date de publication:
Feb 2022
Historique:
revised: 26 03 2021
received: 03 02 2021
accepted: 16 04 2021
pubmed: 20 4 2021
medline: 12 1 2022
entrez: 19 4 2021
Statut: ppublish

Résumé

To compare the sociodemographic characteristics of users of the copper intrauterine device (Cu-IUD) and the levonorgestrel intrauterine system (LNG-IUS) at a family planning clinic in Campinas, SP, Brazil. A retrospective audit study was conducted to analyze the characteristics of new users of IUDs at the clinic of the Department of Obstetrics and Gynecology, University of Campinas. Data covered insertions performed between 1979 and 2006 when only the Cu-IUD was offered at the clinic, and between 2007 and 2019 when the LNG-IUS was also offered, both free of charge to women. Logistic regression analysis was performed. There were 31 385 insertions. Cu-IUD: n = 17 156 (1979-2006) and n = 2013 (2007-2019); LNG-IUS n = 12 216 (2007-2019). Up to 2006, Cu-IUD users were less likely to be nulligravidas, more likely to be younger than 40 years of age, and with fewer years of schooling. Following introduction of LNG-IUS, the sociodemographic characteristics of users presented major changes over time. Comparing the period 1979-2006 with 2007-2019, new users of the LNG-IUS were more likely to be older than 40 years of age, with fewer years of completed schooling, and to be nulligravidas. Major changes in sociodemographic characteristics of users were noted according to preference over time. Introduction of the LNG-IUS presents a major opportunity to increase IUD use.

Identifiants

pubmed: 33872406
doi: 10.1002/ijgo.13716
doi:

Substances chimiques

Contraceptive Agents, Female 0
Levonorgestrel 5W7SIA7YZW

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

240-246

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Fundação de Apoio à Pesquisa do Estado de São Paulo (FAPESP)
ID : 2015/20504-9
Organisme : Brazilian National Research Council (CNPq)
ID : 573747/2008-3

Informations de copyright

© 2021 International Federation of Gynecology and Obstetrics.

Références

Cleland J, Ali M, Benova L, Daniele M. The promotion of intrauterine contraception in low- and middle-income countries: a narrative review. Contraception. 2017;95(6):519-528.
Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998-2007.
Bahamondes L, Faundes A, Sobreira-Lima B, Lui-Filho JF, Pecci P, Matera S. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. Contraception. 2005;72(5):337-341.
McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration approved duration. Am J Obstet Gynecol. 2017;216(6):586.e1-586.e6.
World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), Knowledge for Health Project. Family Planning: A Global Handbook for Providers (2018 update). Baltimore and Geneva: CCP and WHO; 2018.
Park B, Pharm D. Mirena Approved for Pregnancy Prevention for Up to 6 Years. 2020. https://www.empr.com/home/news/mirena-levonorgestrel-releasing-intrauterine-system-pregnancy-prevention/. Accessed September 3, 2020.
Hatcher RA, Trussell J, Nelson AL, et al. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M, eds. Contraceptive Technology. , 20th rev edn. New York, NY: Ardent Media; 2011.
Ali M, Bahamondes L, Bent LS. Extended effectiveness of the etonogestrel-releasing contraceptive implant and the 20 µg levonorgestrel-releasing intrauterine system for 2 years beyond U.S. Food and Drug Administration product labeling. Glob Health Sci Pract. 2017;5(4):534-539.
Diedrich JT, Madden T, Zhao Q, Peipert JF. Long-term utilization and continuation of intra-uterine devices. Am J Obstet Gynecol. 2015;213(6):822.e1-6.
Carr BR, Thomas MA, Gangestad A, et al. Conception rates in women desiring pregnancy after levonorgestrel 52 mg intrauterine system (Liletta®) discontinuation. Contraception. 2021;103(1):26-31.
Bednarek PH, Jensen JT. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. Int J Womens Health. 2009;1:45-58.
Chen BA, Eisenberg DL, Schreiber CA, Turok DK, Olariu AI, Creinin MD. Bleeding changes after levonorgestrel 52-mg intrauterine system insertion for contraception in women with self-reported heavy menstrual bleeding. Am J Obstet Gynecol. 2020;222(4):S888.e1-S888.e6.
Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril. 2018;110(6):1129-1136.
Mandelbaum RS, Ciccone MA, Nusbaum DJ, et al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. Am J Obstet Gynecol. 2020;223(1):103.e1-103.e13.
Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception. 2009;79(1):5-14.
Hubacher D. The Levonorgestrel intrauterine system: Reasons to expand access to the public sector of Africa. Glob Health Sci Pract. 2015;3(4):532-537.
Family Planning Worldwide 2019 Data Sheet. Population Reference Bureau. https://www.prb.org/2019-family-planning-data-sheet-highlights-family-planning-method-use-around-the-world/. Accessed November 20, 2020.
National Survey of Family Growth: Current contraceptive status and method used in month of interview among women 15-44 years of age, Special Tabulation by NCHS. https://www.cdc.gov/nchs/nsfg/key_statistics/c.htm. Accessed November 15 2020.
Ponce de Leon RG, Ewerling F, Serruya SJ, et al. Contraceptive use in Latin America and the Caribbean with a focus on long-acting reversible contraceptives: prevalence and inequalities in 23 countries. Lancet Glob. Health. 2019;7(2):e227-e235.
Hubacher D, Kavanaugh M. Historical record-setting trends in IUD use in the United States. Contraception. 2018;98:467-470.
Rademacher KH, Sripipatana T, Pfitzer A, et al. A global learning agenda for the levonorgestrel intrauterine system (LNG IUS): addressing challenges and opportunities to increase access. Glob Health Sci Pract. 2018;6(4):635-643.
World Health Organization. 19th WHO Model List of Essential Medicines (April. 2015). Geneva, Switzerland: WHO; 2015. Available from https://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf. Accessed June 15, 2020.
Rademacher KH, Solomon M, Brett T, et al. Expanding access to a new, more affordable levonorgestrel intrauterine system in Kenya: Service delivery costs compared with other contraceptive methods and perspectives of key opinion leaders. Glob Health Sci Pract. 2016;4(Suppl 2):S83-S93.
Mendes Ada C, Sá DA, Miranda GM, Lyra TM, Tavares RA. The public healthcare system in the context of Brazil’s demographic transition: current and future demands. Cad Saude Publica. 2012;28(5):955-964.
United Nations - World Population Prospects. Total Fertility Rate. https://www.macrotrends.net/countries/BRA/brazil/fertility-rate. Accessed October 15 2020.
Cavenaghi S, Alves JED. The everlasting outmoded contraceptive method mix in Brazil and its legacy. Rev Bras Estud Popul. 2019;36:1-29.
Buhling KJ, Zite NB, Lotke P, Black K. Worldwide use of intrauterine contraception: a review. Contraception. 2014;89(3):162-173.
Trussell J, Aiken ARA, Micks E, Guthrie KA. Efficacy, safety, and personal considerations. In: Hatcher RA, Nelson AL, Trussell J, eds. Contraceptive Technology, 21st edn. New York, NY: Ayer Company Publishers, Inc.; 2018:95-128.
Hennegan J, Brooks DJ, Schwab KJ, Melendez-Torres GJ. Measurement in the study of menstrual health and hygiene: A systematic review and audit. PLoS One. 2020;15(6):e0232935.
Nanda G, Rademacher KH, Solomon M, Mercer S, Wawire J, Ngahu R. Experiences with the levonorgestrel intrauterine system (LNG-IUS) in Kenya: qualitative interviews with Mirena users and their partners. Eur J Contracept Reprod Health Care. 2018;23(4):303-308.
Hubacher D, Masaba R, Manduku CK, Veena V. Uptake of the levonorgestrel intrauterine system among recent postpartum women in Kenya: factors associated with decision-making. Contraception. 2013;88(1):97-102.
United Nations. Sustainable development goals. SDG indicators. https://unstats.un.org/sdgs/metadata?Text=&Goal=3&Target=3.7. Accessed March 20, 2021.

Auteurs

Montas Laporte (M)

Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.

Sherly Metelus (S)

Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.

Moazzam Ali (M)

Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.

Luis Bahamondes (L)

Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH